John Valliant and his team create next-generation cancer treatments. But he's also training a new generation of scientists and opening doors for researchers working to turn their discoveries into real-world solutions.
A dynamic network of startups coming out of McMaster University — along with an eye- popping takeover of a homegrown success story — is fuelling Hamilton’s rise as a national biotech capital.
Led by CEO John Valliant, the company that develops next-generation precision cancer medicines will become a wholly owned subsidiary of AstraZeneca and continue its operations at its state-of-the-art facility at McMaster Innovation Park.
McMaster logo
McMaster logo
